Full text is available at the source.
Abstract
Obesity-related heart failure with preserved ejection fraction (HFpEF) is characterized by systemic inflammation and reduced functional capacity.
- HFpEF is associated with increased systemic inflammation and decreased ability to function physically.
- Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential to improve symptoms and reduce weight in randomized trials.
- Despite their benefits, the use of GLP-1 RAs in everyday cardiovascular practice remains inconsistent.
Simplified
GLP-1 Therapies